Norelgestromin News
Norelgestromin currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Norelgestromin with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Female contraception. Evra is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.
- Evidence level: L5
- Predicted indications (20):
- amenorrhea (disease) (99.5%)
- acne (disease) (98.5%)
- breast fibrocystic disease (97.5%)
- apocrine adenosis of breast (96.2%)
- blunt duct adenosis of breast (96.2%)
- benign mammary dysplasia (95.9%)
- breast abscess (95.4%)
- fat necrosis of breast (95.4%)
- lactation disease (95.2%)
- primary ovarian failure (95.1%)
- breast adenosis (95.0%)
- scalp dermatosis (94.4%)
- tetragametic chimerism (93.8%)
- ovarian remnant syndrome (93.5%)
- anovulation (93.5%)
- symptomatic form of fragile X syndrome in female carrier (93.5%)
- partial trisomy/tetrasomy of the short arm of chromosome 12 (93.5%)
- partial trisomy/tetrasomy of the short arm of chromosome 18 (93.4%)
- partial trisomy/tetrasomy of the short arm of chromosome 5 (93.4%)
- polysomy of X chromosome (93.2%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.